Obesity and the metabolic syndrome in the elderly - A mini-review

Gerontology

Volumn 54, Issue 5, 2008, Pages 253-259

  Lechleitner, Monika ^a  

^a Hospital Hochzirl   (Austria)

Author keywords

Metabolic syndrome; Obesity

Indexed keywords

GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; METFORMIN;

CARDIOVASCULAR RISK; COMORBIDITY; DRUG HALF LIFE; EXERCISE; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; METABOLIC SYNDROME X; MORBIDITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PREVALENCE; PRIORITY JOURNAL; SHORT SURVEY; WEIGHT REDUCTION;

AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; HUMANS; METABOLIC SYNDROME X; OBESITY; PREVALENCE; RISK FACTORS;

EID: 53649107880     PISSN: 0304324X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000161734     Document Type: Short Survey

References (71)

1. Rössner S: Obesity in the elderly - a future matter of concern? Obes Rev 2001;2:183-188.
2. Villareal DT, Apovian CM, Kushner RF, Klein S: Obesity in older adults: technical review and position statement of the American Society for Nutrition and NAASO, The Obesity Society. Am J Clin Nutr 2005;82:923-934.
3. Facchini FS, Hu N, Abbasi F, Reaven GM: Insulin resistance as a predictor of age-related diseases. J Clin Endocrinol Metab 2001;86:3574-3578.
4. Reaven GM: Banting Lecture 1988. The role of insulin resistance in human disease. Diabetes 1988;37:1595-1607.
5. Eckel RH, Grundy SM, Zimmet PZ: The metabolic syndrome. Lancet 2005;365:1415-1428.
6. Hu G, Qiao Q, Tuomilheto J, Balkau B, Borch-Johnsen K, Pyorala K: Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in non-diabetic European men and women. Arch Intern Med 2004;164:1066-1076.
7. Grundy SM: Metabolic syndrome pandemia. Arterioscler Thromb Vasc Biol 2008;28:629-632.
8. McNeill AM, Katz R, Girman CJ, Rosamond WD, Wagenknecht LE, Barzilay JI, Tracy RP, Savage PJ, Jackson SA: Metabolic syndrome and cardiovascular disease in older people: the cardiovascular health study. J Am Geriatr Soc 2006;54:1317-1324.
9. Yaffe K: Metabolic syndrome and cognitive disorders. Alzheimer Dis Assoc Disord 2007;21:167-171.
10. Executive Summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497.
11. Alberti KG, Zimmet P, Shaw J; IDF Epidemiology Task Force Consensus Group: The metabolic syndrome - a new worldwide definition. Lancet 2005;366:1059-1062.
12. Després JP, Lemieux I: Abdominal obesity and metabolic syndrome. Nature 2006;444:881-887.
13. Monami M, Marchionni N, Masotti G, Mannucci E: IDF and ATP-III definitions of metabolic syndrome in the prediction of allcause mortality in type 2 diabetic patients. Diabetes Obes Metab 2007;9:350-353.
14. Motta M, Bennati E, Cardillo E, Passamonte M, Ferlito L, Malaguarnera M: The metabolic syndrome in the elderly: considerations on the diagnostic criteria of the International Diabetes Federation and some proposed modifications. Arch Gerontol Geriatr 2008 (in press).
15. World Health Organization: Obesity: Preventing and Managing the Global Epidemic. Report of a WHO Consultation on Obesity. Geneva, WHO, 1998.
16. Willett WC, Dietz WH, Colditz GA: Guidelines for healthy weight. N Engl J Med 1999;341:427-439.
17. Volkert D, Berner YN, Berry E, et al: ESPEN guidelines on enteral nutrition: geriatrics. Clin Nutr 2006;25:330-360.
18. Heiat A, Vaccarino V, Krumholz HM: An evidence-based assessment of federal guidelines for overweight and obesity as they apply to elderly persons. Arch Intern Med 2001;161:1194-1203.
19. Harris TB, Launer LJ, Madans J, Feldman JJ: Cohort study of effect of being overweight and change in weight on risk of coronary heart disease in old age. BMJ 1997;314:1791-1794.
20. Manson JE, Willett WC, Stampfer MJ, Colditz GA, Hunter DJ, Hankinson SE, Hennekens CH, Speizer FE: Body weight and mortality among women. N Engl J Med 1995;333:677-685.
21. Grinker JA, Tucker K, Vokonas PS, Rush D: Body habitus changes among adult males from the normative aging study: relations to aging, smoking history and alcohol intake. Obes Res 1995;3:435-446.
22. Kannel WB, Gordon T, Castelli WP: Obesity, lipids, and glucose intolerance. The Framingham Study. Am J Clin Nutr 1979;32:1238-1245.
23. Fogelholm M, Kujala U, Kaprio J, Sarna S: Predictor of weight change in middle-aged and old men. Obes Rev 2000;8:367-373.
24. Visser M, Langlois J, Guralnik JM, Cauley JA, Kronmal RA, Robbins J, Williamson JD: High body fatness, but not low fat-free mass, predicts disability in older men and women: the Cardiovascular Health Study. Am J Clin Nutr 1998;68:584-590.
25. Bo M, Sona A, Astengo M, Fiandra U, Quagliotti E, Brescianini A, Fonte G: Metabolic syndrome in older subjects: coincidence or clustering? Arch Gerontol Geriatr 2008 (in press).
26. Alexander CM, Landsman PB, Grundy SM: The influence of age and body mass index on the metabolic syndrome and its components. Diabetes Obes Metab 2008;10:246-250.
27. Ford ES, Giles WH, Dietz WH: Prevalence of the metabolic syndrome among US adults: findings from the Third National Health and Nutrition Examination Survey. JAMA 2002;287:356-359.
28. Stunkard AJ, Sorensen TI, Hanis C, et al: An adoption study of human obesity. N Engl J Med 1986;314:193-198.
29. Stunkard AJ, Harris JR, Pedersen NL, McClearn GE: The body mass index of twins who have been reared apart. N Engl J Med 1990;322:1483-1487.
30. Körner A, Kiess W, Stumvoll M, Kovacs P: Polygenic contribution to obesity: genomewide strategies reveal new targets. Front Horm Res 2008;36:12-36.
31. Christakis NA, Fowler JM: The spread of obesity in a large social network over 32 years. N Engl J Med 2007;357:370-374.
32. Havel PJ: Update on adipocyte hormones; regulation of energy balance and carbohydrate/ lipid metabolism. Diabetes 2004;53:S143-S151.
33. Matsuzawa Y, Funahashi T, Kimara S, Shimomura I: Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol 2004;24:29-33.
34. Ridker PM: Inflammatory biomarkers and risk for myocardial infarction, stroke, diabetes and total mortality: implications for longevity. Nutr Rev 2007;65:S253-S259.
35. Dyck DJ, Heigenhauser GJ, Bruce CR: The role of adipokines as regulators of skeletal muscle fatty acid metabolism and insulin sensitivity. Acta Physiol 2006;186:5-16.
36. Grimble RF: Inflammatory status and insulin resistance. Curr Opin Clin Nutr Metab Care 2002;5:551.
37. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM: Increased adipose tissue expression of tumor necrosis factor-α in human obesity and insulin resistance. J Clin Invest 1995;95:2409-2415.
38. Moschen AR, Kaser A, Enrich B, et al: Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol 2007;178:1748-1758.
39. Gustafson B, Hammarstedt A, Andersson CX, Smith U: Inflamed adipose tissue: a culprit underlying the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol 2007;27:2276-2283.
40. Boden R, Shulman GI: Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin-resistance and β-cell dysfunction. Eur J Clin Invest 2002;32(suppl 3):14-23.
41. Friedman J: Fat in all the wrong places. Nature 2002;415:268-269.
42. Unger RM: Lipid overload and overflow: metabolic trauma and the metabolic syndrome. Themes Endocrinol Metab 2003;14:398-403.
43. Slawik M, Vidal-Puig AJ: Lipotoxicity, overnutrition and energy metabolism in aging. Aging Res Rev 2006;5:144-154.
44. Beaufrère B, Morio B: Fat and protein redistribution with aging: metabolic considerations. Eur J Clin Nutr 2000;54(suppl):S48-S53.
45. Schwartz RS: Trophic factor supplementation: effect on the age-associated changes in body composition. J Gerontol A Biol Sci Med Sci 1995;50:151-156.
46. Moller N, O'Brien P, Nair KS: Disruption of the relationship between fat content and leptin levels with aging in humans. J Clin Endocrinol Metab 1998;83:931-934.
47. Kim J, Wei Y, Sowers JR: Role of mitochondrial dysfunction in insulin resistance. Circ Res 2008;102:401-414.
48. Petersen KF, Befroy D, Dufour S, Dziura J, Ariyan C, Rothman DL, DiPietro L, Cline GW, Shulman GI: Mitochondrial dysfunction in the elderly: possible role in insulin resistance. Science 2003;300:1140-1142.
49. Galani C, Schneider H: Prevention and treatment of obesity with lifestyle interventions: review and meta-analysis. Int J Public Health 2007;52:348-359.
50. Tuomilehto J, Lindström J, Eriksson JG, et al; Finnish Diabetes Prevention Study Group: Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343-1350.
51. Knowler WJ, Barrett-Connor E, Fowler SE, et al; Diabetes Prevention Program Research Group: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.
52. Li G, Zhang P, Wang J, Gregg EW, Yang W, Gong Q, et al: The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study. Lancet 2008;371:1783-1789.
53. Jensen GL, Roy MA, Buchanan AE, Berg WB: Weight loss intervention for obese older women: improvements in performance and function. Obes Res 2004;12:1814-1820.
54. Grant RW, Meigs JB: Should the insulin resistance syndrome be treated in the elderly? Drugs Aging 2004;21:141-151.
55. Hainer V, Toplak H, Mitrakou A: Treatment modalities of obesity. Diabetes Care 2008; 31(suppl 2):S269-S272.
56. Mattila K, Haavisto M, Rajala S: Body mass index and mortality in the elderly. BMJ 1986;292:876-878.
57. Rissanen A, Knekt P, Heliövaara M, Aromaa A, Reunanen A, Maatela J: Weight and mortality in Finnish women. J Clin Epidemiol 1991;44:787-795.
58. Carr DB, Utzschneider KM, Hull RL, Kodama K, Retzlaff BM, Brunzell JD, Shofer JB, Fish BE, Knopp RH, Kahn SE: Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome. Diabetes 2004;53:2087-2097.
59. Goodpaster BH, Krishnaswami S, Harris TB, Katsiaras A, Kritchevsky SB, Smansick EM, Nevitt M, Holvoet P, Newman AB: Obesity, regional fat distribution, and the metabolic syndrome in older men and women. Arch Intern Med 2005;165:777-783.
60. Wadden TA, Berkowitz RI, Woble LG, Sarwer TB, Phelan S, Cato RK, Hesson LA, Osei SY, Kaplan R, Stunkard AJ: Randomised trial of lifestyle modification and pharmacotherapy for obesity. N Engl J Med 2005;353:2111-2120.
61. Didangelos TP, Thanopoulou AK, Bousboulas SH, Sambanis CL, Athyros VG, Spanou EA, Dimitiou KC, Pappas SI, Karamanos BG, Karamitsos DT: The ORLIstat and CARdiovascular risk profile in patients with metabolic syndrome and type 2 DIAbetes (ORLICARDIA) study. Curr Med Res Opin 2004;20:1393-1401.
62. Van Gaal L: Reducing the cardiometabolic risk through selective antagonism of CB1 receptors. Clin Cornerstone 2002;6(suppl):S24-S29.
63. Lakka TA, Laaksonen DE, Lakka HM, Männikkö N, Niskanen LK, Rauramaa R, Salonen JT: Sedentary lifestyle, poor cardiorespiratory fitness, and the metabolic syndrome. Med Sci Sports Exerc 2003;35:1279-1286.
64. Strath S, Swartz A, Parker S, Miller N, Cieslik L: Walking and the metabolic syndrome in older adults. J Phys Act Health 2007;4:397-410.
65. Short KR, Vittone JL, Bigelow ML, Proctor DN, Rizza RA, Coenen-Schimke JM, Nair KS: Impact of aerobic exercise training on age-related changes in insulin sensitivity and muscle oxidation capacity. Diabetes 2003;52:1888-1896.
66. Orchard TJ, Temprosa M, Goldberg R, Haffner S, Ratner R, Marcovina S, Fowler S; Diabetes Prevention Program Research Group: The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann Intern Med 2005;142:611-619.
67. Eguchi K, Tomizawa H, Ishikawa J, Hashide S, Numao T, Fukada T, Shimada K, Kario K: Comparison of the effects of pioglitazone and metformin on insulin resistance and hormonal markers in patients with impaired glucose tolerance and early diabetes. Hypertens Res 2007;30:23-30.
68. Riddle MC, Drucker DJ: Emerging therapies mimicking the effects of amylin and glucagon-like peptide-1. Diabetes Care 2006;29:435-439.
69. Cheng AY, Leiter LA: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Curr Opin Cardiol 2006;21:400-404.
70. Tomkin GH: Targets for intervention in dyslipidemia in diabetes. Diabetes Care 2008;31(suppl 2):S241-S248.
71. Ferdinand KC: Management of cardiovascular risk in patients with type 2 diabetes mellitus as a component of the cardiometabolic syndrome. J Cardiometab Syndr 2006;1:133-140.